149 related articles for article (PubMed ID: 10396496)
21. Cost-benefit analysis of hyperphenylalaninemia due to 6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency: for consideration of expanded newborn screening in Hong Kong.
Lee HH; Mak CM; Poon GW; Wong KY; Lam CW
J Med Screen; 2014 Jun; 21(2):61-70. PubMed ID: 24803483
[TBL] [Abstract][Full Text] [Related]
22. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
23. Neonatal biochemical screening for disease.
Clague A; Thomas A
Clin Chim Acta; 2002 Jan; 315(1-2):99-110. PubMed ID: 11728413
[TBL] [Abstract][Full Text] [Related]
24. Phenylketonuria (PKU): screening and management.
NIH Consens Statement; 2000 Oct 16-18; 17(3):1-33. PubMed ID: 11757784
[TBL] [Abstract][Full Text] [Related]
25. Phenylketonuria in South Africa. A report on the status quo.
Hitzeroth HW; Niehaus CE; Brill DC
S Afr Med J; 1995 Jan; 85(1):33-6. PubMed ID: 7784915
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington State.
Ding Y; Thompson JD; Kobrynski L; Ojodu J; Zarbalian G; Grosse SD
J Pediatr; 2016 May; 172():127-35. PubMed ID: 26876279
[TBL] [Abstract][Full Text] [Related]
27. [Cost/benefit study of the neonatal detection of phenylketonuria and hypothyroidism].
Dhondt JL; Farriaux JP; Lebrun T; Sailly JC
Pediatrie; 1988; 43(4):345-8. PubMed ID: 3138627
[TBL] [Abstract][Full Text] [Related]
28. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
[TBL] [Abstract][Full Text] [Related]
29. Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi - a systematic review and economic evaluation.
Stevenson M; Pandor A; Martyn-St James M; Rafia R; Uttley L; Stevens J; Sanderson J; Wong R; Perkins GD; McMullan R; Dark P
Health Technol Assess; 2016 Jun; 20(46):1-246. PubMed ID: 27355222
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of expanded newborn screening in Texas.
Tiwana SK; Rascati KL; Park H
Value Health; 2012; 15(5):613-21. PubMed ID: 22867769
[TBL] [Abstract][Full Text] [Related]
31. The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model.
Bond M; Mealing S; Anderson R; Elston J; Weiner G; Taylor RS; Hoyle M; Liu Z; Price A; Stein K
Health Technol Assess; 2009 Sep; 13(44):1-330. PubMed ID: 19799825
[TBL] [Abstract][Full Text] [Related]
32. Costing model for neonatal screening and diagnosis of haemoglobinopathies.
Cronin EK; Normand C; Henthorn JS; Hickman M; Davies SC
Arch Dis Child Fetal Neonatal Ed; 1998 Nov; 79(3):F161-7. PubMed ID: 10194984
[TBL] [Abstract][Full Text] [Related]
33. Economic model of a birth cohort screening program for hepatitis C virus.
McGarry LJ; Pawar VS; Panchmatia HR; Rubin JL; Davis GL; Younossi ZM; Capretta JC; O'Grady MJ; Weinstein MC
Hepatology; 2012 May; 55(5):1344-55. PubMed ID: 22135116
[TBL] [Abstract][Full Text] [Related]
34. Costs and outcomes over 36 years of patients with phenylketonuria who do and do not remain on a phenylalanine-restricted diet.
Guest JF; Bai JJ; Taylor RR; Sladkevicius E; Lee PJ; Lachmann RH
J Intellect Disabil Res; 2013 Jun; 57(6):567-79. PubMed ID: 22563770
[TBL] [Abstract][Full Text] [Related]
35. First estimates of the potential cost and cost saving of protecting childhood hearing from damage caused by congenital CMV infection.
Williams EJ; Gray J; Luck S; Atkinson C; Embleton ND; Kadambari S; Davis A; Griffiths P; Sharland M; Berrington JE; Clark JE
Arch Dis Child Fetal Neonatal Ed; 2015 Nov; 100(6):F501-6. PubMed ID: 26122458
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness Methods and Newborn Screening Assessment.
Castilla-Rodríguez I; Vallejo-Torres L; Couce ML; Valcárcel-Nazco C; Mar J; Serrano-Aguilar P
Adv Exp Med Biol; 2017; 1031():267-281. PubMed ID: 29214578
[TBL] [Abstract][Full Text] [Related]
37. Expanding screening for rare metabolic disease in the newborn: an analysis of costs, effect and ethical consequences for decision-making in Finland.
Autti-Rämö I; Mäkelä M; Sintonen H; Koskinen H; Laajalahti L; Halila R; Kääriäinen H; Lapatto R; Näntö-Salonen K; Pulkki K; Renlund M; Salo M; Tyni T
Acta Paediatr; 2005 Aug; 94(8):1126-36. PubMed ID: 16188860
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
Chambers M; Hutton J; Gladman J
Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):577-93. PubMed ID: 10662482
[TBL] [Abstract][Full Text] [Related]
39. Neonatal screening and long-term follow-up of phenylketonuria: the French database.
Abadie V; Berthelot J; Feillet F; Maurin N; Mercier A; de Baulny HO; de Parscau L
Early Hum Dev; 2001 Dec; 65(2):149-58. PubMed ID: 11641035
[TBL] [Abstract][Full Text] [Related]
40. The safety and effectiveness of different methods of earwax removal: a systematic review and economic evaluation.
Clegg AJ; Loveman E; Gospodarevskaya E; Harris P; Bird A; Bryant J; Scott DA; Davidson P; Little P; Coppin R
Health Technol Assess; 2010 Jun; 14(28):1-192. PubMed ID: 20546687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
